TheraCryf PLC (FWB:8EV) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares (Placing Shares and Subscription Shares) Announced: about £1.05M · GBX 0.18 a share · Turner Pope +1 Dealers: Turner Pope (lead), Singer Capital Markets (co-lead) Buyers: Northern Standard Limited (138,888,888 Subscription Shares; 20.8% of Enlarged Share Capital following Admission); Dr Huw Jones (5,555,555 Subscription Shares); Toni Haenninen (via Borealito GmbH) (4,444,444 Subscription Shares); Dr Alastair Smith (13,888,888 Subscription Shares); Dr Nicholas Mallard (2,777,777 Subscription Shares); Dr Glen Clack (1,388,888 Subscription Shares); Dr Helen Kuhlman (3,333,333 shares) Insiders: Certain PDMRs to subscribe for an aggregate 28,055,552 New Ordinary Shares through the PDMR Subscription Use of proceeds: Complete clinic-enabling programme for Ox-1 addiction asset, apply for Phase 1 approval in Australia, and extend cash runway to end Q1 2027 | Aug 20, 2026 | US$1.43M |
| Private placement of new ordinary shares Update: £4.25M · £0.0025 a share · Turner Pope Investments (TPI) Limited Dealers: Turner Pope Investments (TPI) Limited (lead) Buyers: Tracarta Limited (£1,000,000 for 400,000,000 new Ordinary Shares); Dr Alastair Smith (4,000,000 Ordinary Shares); Dr Huw Jones; Toni Hänninen Insiders: Directors and PDMRs subscribing £28,000 for 11,200,000 new Ordinary Shares; a related party transaction Use of proceeds: Pre-clinical development of Ox-1 orexin-1 antagonist, SFX-01 tablet manufacturing, patent portfolio, consultants and general corporate purposes | Mar 7, 2025 | US$5.35M |